Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Anti-PD1/PD-L1 immunotherapy is a standard treatment for stage III-IV non-small cell lung cancer (NSCLC).
• Patient selection for immunotherapy typically relies on PD-L1 expression and tumor mutational burden.
• Oncogenic driver mutations can influence the tumor immune microenvironment and affect immunotherapy response.

Purpose of the Study:

• To review the molecular mechanisms by which oncogenic driver mutations (EGFR, ALK, BRAF, MET) affect the tumor immune microenvironment in NSCLC.
• To discuss how these mutations may contribute to resistance against anti-PD1/PD-L1 immunotherapy.
• To provide an overview of current clinical data regarding anti-PD1/PD-L1 efficacy in NSCLC patients with oncogenic driver mutations.

Main Methods:

• Literature review of molecular mechanisms.
• Analysis of existing clinical data.
• Synthesis of information on immune microenvironment modulation by driver mutations.

Main Results:

• Oncogenic driver mutations alter the tumor immune microenvironment.
• These alterations can impede the efficacy of anti-PD1/PD-L1 therapies.
• Clinical data show variable responses to immunotherapy in NSCLC with driver mutations.

Conclusions:

• Understanding the impact of oncogenic driver mutations on the immune microenvironment is crucial for predicting anti-PD1/PD-L1 therapy response in NSCLC.
• Further research is needed to develop strategies to overcome resistance in these patient populations.